Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Research output: Contribution to journalJournal articlepeer-review

Standard

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. / Holst, Jens Juul; Deacon, Carolyn F.

In: Current Opinion in Pharmacology, Vol. 4, No. 6, 2004, p. 589-96.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Holst, JJ & Deacon, CF 2004, 'Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.', Current Opinion in Pharmacology, vol. 4, no. 6, pp. 589-96. https://doi.org/10.1016/j.coph.2004.08.005

APA

Holst, J. J., & Deacon, C. F. (2004). Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacology, 4(6), 589-96. https://doi.org/10.1016/j.coph.2004.08.005

Vancouver

Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacology. 2004;4(6):589-96. https://doi.org/10.1016/j.coph.2004.08.005

Author

Holst, Jens Juul ; Deacon, Carolyn F. / Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. In: Current Opinion in Pharmacology. 2004 ; Vol. 4, No. 6. pp. 589-96.

Bibtex

@article{e0cdbf20ab4b11ddb5e9000ea68e967b,
title = "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.",
abstract = "Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.",
author = "Holst, {Jens Juul} and Deacon, {Carolyn F}",
note = "Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Great Britain; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors",
year = "2004",
doi = "10.1016/j.coph.2004.08.005",
language = "English",
volume = "4",
pages = "589--96",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier Ltd. * Current Opinion Journals",
number = "6",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

AU - Holst, Jens Juul

AU - Deacon, Carolyn F

N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Great Britain; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors

PY - 2004

Y1 - 2004

N2 - Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

AB - Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

U2 - 10.1016/j.coph.2004.08.005

DO - 10.1016/j.coph.2004.08.005

M3 - Journal article

C2 - 15525549

VL - 4

SP - 589

EP - 596

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 6

ER -

ID: 8417324